Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845805 · ClinicalTrials.gov registry record · Phase 2
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT01845805 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 49 participants.
The verdict
NCT01845805, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as compared to observation after completion of adjuvant therapy.
Interventions
- OTHER Observation
- DRUG oral azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2014-01-10 |
| Est. Completion | 2021-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845805
The ClinicalTrials.gov registry entry for NCT01845805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Observation is the first listed.
NCT01845805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01845805 about?
NCT01845805 is a clinical study titled "Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)". To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as compared to observation after completion of adjuvant therapy.
What is the current status of trial NCT01845805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2014-01-10. Estimated completion is 2021-04-09.
What interventions are being tested in trial NCT01845805?
The interventions under investigation include: Observation (OTHER), oral azacitidine (DRUG).
Who is sponsoring clinical trial NCT01845805?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.